JP2019522024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522024A5 JP2019522024A5 JP2019503999A JP2019503999A JP2019522024A5 JP 2019522024 A5 JP2019522024 A5 JP 2019522024A5 JP 2019503999 A JP2019503999 A JP 2019503999A JP 2019503999 A JP2019503999 A JP 2019503999A JP 2019522024 A5 JP2019522024 A5 JP 2019522024A5
- Authority
- JP
- Japan
- Prior art keywords
- transdermal delivery
- salt
- therapeutic agent
- drug reservoir
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 72
- 230000037317 transdermal delivery Effects 0.000 claims description 45
- 229940124597 therapeutic agent Drugs 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 30
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 24
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 239000002585 base Substances 0.000 claims description 15
- 239000004821 Contact adhesive Substances 0.000 claims description 14
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 12
- 229960003530 donepezil Drugs 0.000 claims description 8
- 229960004640 memantine Drugs 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 208000017667 Chronic Disease Diseases 0.000 claims description 7
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 claims description 7
- 239000001069 triethyl citrate Substances 0.000 claims description 7
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000013769 triethyl citrate Nutrition 0.000 claims description 7
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 6
- 150000001447 alkali salts Chemical class 0.000 claims description 6
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002367 Polyisobutene Polymers 0.000 claims description 4
- 229920000249 biocompatible polymer Polymers 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960003135 donepezil hydrochloride Drugs 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- 229920005549 butyl rubber Polymers 0.000 claims description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 229960000967 memantine hydrochloride Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- -1 polybutylene Polymers 0.000 claims description 2
- 229920001748 polybutylene Polymers 0.000 claims description 2
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 2
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 claims description 2
- 159000000011 group IA salts Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000007792 addition Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022025574A JP2022060428A (ja) | 2016-07-27 | 2022-02-22 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2024000683A JP2024019737A (ja) | 2016-07-27 | 2024-01-05 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367502P | 2016-07-27 | 2016-07-27 | |
| US201662367542P | 2016-07-27 | 2016-07-27 | |
| US62/367,542 | 2016-07-27 | ||
| US62/367,502 | 2016-07-27 | ||
| US201662423133P | 2016-11-16 | 2016-11-16 | |
| US62/423,133 | 2016-11-16 | ||
| US201762457794P | 2017-02-10 | 2017-02-10 | |
| US62/457,794 | 2017-02-10 | ||
| US201762504408P | 2017-05-10 | 2017-05-10 | |
| US201762504391P | 2017-05-10 | 2017-05-10 | |
| US62/504,391 | 2017-05-10 | ||
| US62/504,408 | 2017-05-10 | ||
| PCT/US2017/044047 WO2018022814A1 (en) | 2016-07-27 | 2017-07-26 | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025574A Division JP2022060428A (ja) | 2016-07-27 | 2022-02-22 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2024000683A Division JP2024019737A (ja) | 2016-07-27 | 2024-01-05 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522024A JP2019522024A (ja) | 2019-08-08 |
| JP2019522024A5 true JP2019522024A5 (enExample) | 2020-08-27 |
| JP7469879B2 JP7469879B2 (ja) | 2024-04-17 |
Family
ID=59593165
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503999A Active JP7469879B2 (ja) | 2016-07-27 | 2017-07-26 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2022025574A Pending JP2022060428A (ja) | 2016-07-27 | 2022-02-22 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2024000683A Pending JP2024019737A (ja) | 2016-07-27 | 2024-01-05 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025574A Pending JP2022060428A (ja) | 2016-07-27 | 2022-02-22 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| JP2024000683A Pending JP2024019737A (ja) | 2016-07-27 | 2024-01-05 | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180028461A1 (enExample) |
| EP (1) | EP3490559A1 (enExample) |
| JP (3) | JP7469879B2 (enExample) |
| KR (1) | KR102424270B1 (enExample) |
| CN (1) | CN109789134A (enExample) |
| AU (2) | AU2017302305A1 (enExample) |
| CA (1) | CA3031944A1 (enExample) |
| WO (1) | WO2018022814A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014014753A1 (en) * | 2012-07-17 | 2014-01-23 | Dow Global Technologies Llc | Composition comprising an organic liquid diluent and a cellulose ether of very low viscosity |
| US10966936B2 (en) | 2015-12-30 | 2021-04-06 | Corium, Inc. | Systems comprising a composite backing and methods for long term transdermal administration |
| CA3028436A1 (en) | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| MX2019001104A (es) | 2016-07-27 | 2019-10-02 | Corium Int Inc | Sistemas de suministro transdermico de memantina. |
| US9993466B2 (en) * | 2016-07-27 | 2018-06-12 | Corium International, Inc. | Donepezil transdermal delivery system |
| KR102506333B1 (ko) | 2016-12-20 | 2023-03-06 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀을 함유하는 경피흡수 치료 시스템 |
| CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
| EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| KR102372630B1 (ko) * | 2019-05-15 | 2022-03-14 | 주식회사 대웅제약 | 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제 |
| US20210000754A1 (en) * | 2019-07-02 | 2021-01-07 | Clifford T. Rowley | Transdermal patch providing improved permeability and composition |
| BR112022007369A2 (pt) * | 2019-10-24 | 2022-07-05 | Lts Lohmann Therapie Systeme Ag | Sistema terapêutico transdérmico para a administração transdérmica de fingolimode |
| CN112915071A (zh) * | 2019-11-20 | 2021-06-08 | 成都康弘药业集团股份有限公司 | 一种含有美金刚的透皮贴剂 |
| CA3255420A1 (en) * | 2022-03-14 | 2023-09-21 | Arx Llc | TRANSDERMAL ADMINISTRATION SYSTEMS FOR CERTAIN FACTOR XA INHIBITORS AND ASSOCIATED METHODS FOR THEIR PREPARATION AND USE |
| KR20240146479A (ko) * | 2023-03-29 | 2024-10-08 | 아이큐어 주식회사 | 고용량 도네페질 약물탑재 지속방출 경피흡수제제 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| NL134681C (enExample) | 1966-04-26 | |||
| US3546141A (en) | 1966-08-08 | 1970-12-08 | Mc Donnell Douglas Corp | Phosphorus-nitrogen polymers and process |
| CH603545A5 (enExample) | 1972-04-20 | 1978-08-31 | Merz & Co | |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| ATE45735T1 (de) | 1984-12-22 | 1989-09-15 | Thomae Gmbh Dr K | Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel. |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4781924A (en) | 1987-11-09 | 1988-11-01 | Alza Corporation | Transdermal drug delivery device |
| US4837027A (en) | 1987-11-09 | 1989-06-06 | Alza Corporation | Transdermal drug delivery device |
| US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
| ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
| US5252588A (en) | 1990-04-27 | 1993-10-12 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation |
| ATE111351T1 (de) | 1990-07-23 | 1994-09-15 | Alza Corp | Oral anzuwendende osmotische vorrichtung zur abgabe von nicotin. |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5123900A (en) | 1991-08-16 | 1992-06-23 | Bertek, Inc. | Moisture permeable double disk |
| US5424077A (en) | 1993-07-13 | 1995-06-13 | Church & Dwight Co., Inc. | Co-micronized bicarbonate salt compositions |
| JP4102901B2 (ja) | 1994-09-14 | 2008-06-18 | スリーエム カンパニー | 経皮薬剤導入用マトリックス |
| WO1996040087A2 (en) | 1995-06-07 | 1996-12-19 | Cygnus, Inc. | Pressure sensitive acrylate adhesive composition cross-linked with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
| DE19531342B4 (de) | 1995-08-25 | 2007-11-29 | Merz Pharma Gmbh & Co. Kgaa | Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren |
| US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
| ATE229817T1 (de) | 1996-10-24 | 2003-01-15 | Alza Corp | Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung |
| US5866585A (en) | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
| US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US20020192243A1 (en) * | 1999-12-16 | 2002-12-19 | Tsung-Min Hsu | Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers |
| US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
| US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| EP1390085B1 (en) | 2001-05-01 | 2009-08-05 | A.V. Topchiev Institute of Petrochemical Synthesis | Hydrogel compositions |
| US7250394B2 (en) | 2001-08-20 | 2007-07-31 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| JP2005501883A (ja) | 2001-09-04 | 2005-01-20 | トロムスドルフ ゲーエムベーハー ウント コンパニー カーゲー アルツナイミッテル | セルタコナゾールを含む爪の機能障害および疾患の治療用の膏薬 |
| US7273619B2 (en) | 2002-01-17 | 2007-09-25 | Samyang Corporation | Transdermal composition of an antivomiting agent |
| CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| CN1870984A (zh) | 2003-10-22 | 2006-11-29 | 莫茨药物股份两合公司 | 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途 |
| EP1952824A1 (en) | 2003-11-21 | 2008-08-06 | Memory Pharmaceuticals Corporation | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors |
| US7176185B2 (en) | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
| EP1715853A4 (en) | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF |
| US7670838B2 (en) | 2004-05-24 | 2010-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Coupling of excitation and neurogenesis in neural stem/progenitor cells |
| JPWO2005115355A1 (ja) | 2004-05-28 | 2008-03-27 | 久光製薬株式会社 | 貼付製剤 |
| TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| MX2007004315A (es) | 2004-10-08 | 2008-03-11 | Noven Pharma | Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo. |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US7462743B2 (en) | 2005-01-11 | 2008-12-09 | Teva Pharmaceutical Fine Chemicals S.R.L. | Polymorphs of memantine hydrochloride |
| BRPI0607017B8 (pt) | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
| US7888422B2 (en) | 2005-11-09 | 2011-02-15 | Mylan Technologies Inc. | Long-wearing removable pressure sensitive adhesive |
| IL175338A0 (en) | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
| ES2466647T3 (es) | 2006-05-08 | 2014-06-10 | Teikoku Seiyaku Co., Ltd. | Preparación absorbible por vía transdérmica que comprende un agente contra la demencia |
| JP5097359B2 (ja) | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | ドネペジル経皮吸収型製剤 |
| US9248104B2 (en) | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
| US20080107719A1 (en) | 2006-11-08 | 2008-05-08 | Sukhon Likitlersuang | Transdermal drug delivery system |
| CN101573115B (zh) * | 2006-12-01 | 2012-06-06 | 日东电工株式会社 | 抑制含有多奈哌齐的贴剂着色的方法、及降低多奈哌齐类似物的生成量的方法 |
| KR101408488B1 (ko) | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법 |
| BRPI0719351A2 (pt) | 2006-12-01 | 2014-01-07 | Nitto Denko Corp | Preparação adesiva estabilizada contendo donezepil |
| BRPI0814697B8 (pt) | 2007-07-10 | 2021-05-25 | Agile Therapeutics Inc | dispositivo de liberação de fármacos |
| DE102008013701A1 (de) | 2008-03-11 | 2009-09-17 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System mit stabilisierter Membran |
| PE20100371A1 (es) * | 2008-10-31 | 2010-06-01 | Lexicon Pharmaceuticals Inc | Agonistas del receptor s1p para el tratamiento de malaria cerebral |
| US20100178037A1 (en) | 2009-01-12 | 2010-07-15 | Te-Wei Chen | Display apparatus, video generation apparatus, and method thereof |
| AU2010204986B2 (en) | 2009-01-14 | 2016-06-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
| JP5758290B2 (ja) | 2009-05-01 | 2015-08-05 | 久光製薬株式会社 | 経皮吸収型製剤 |
| ES2652491T3 (es) | 2009-10-21 | 2018-02-02 | Teikoku Seiyaku Co., Ltd. | Preparación que contiene donepecilo de absorción transdérmica |
| CN102048678A (zh) | 2009-10-30 | 2011-05-11 | 北京隆旗生物科技有限公司 | 一种奥昔布宁的透皮吸收制剂及其制备方法与药物应用 |
| GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
| JP2012236773A (ja) * | 2009-12-16 | 2012-12-06 | Goto Takeshi | 抗認知症薬物の経皮吸収製剤 |
| PT2519225E (pt) | 2009-12-30 | 2015-07-27 | Novartis Ag | Tiras finas de nicotina extrudidas por fusão |
| US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| JP5665861B2 (ja) * | 2010-04-28 | 2015-02-04 | 久光製薬株式会社 | ドネペジル含有経皮吸収製剤 |
| US9012511B2 (en) | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| US20140370076A1 (en) | 2010-06-30 | 2014-12-18 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
| JP5699554B2 (ja) | 2010-11-11 | 2015-04-15 | 富士通株式会社 | ベクトル処理回路、命令発行制御方法、及びプロセッサシステム |
| TWI433904B (zh) | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | 多奈哌齊經皮貼片 |
| US8673338B2 (en) | 2011-07-29 | 2014-03-18 | Massachusetts Eye And Ear Infirmary | Methods of delivering pharmaceutical agents |
| KR101239150B1 (ko) | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
| TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| EP3054933A4 (en) * | 2013-10-11 | 2017-03-15 | Teikoku Pharma USA, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
| KR101485822B1 (ko) | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | 도네페질 또는 그의 염을 함유하는 경피흡수제제 |
| CN107106510A (zh) | 2014-12-18 | 2017-08-29 | Icure药品株式会社 | 含有多奈哌齐为有效成分的经皮吸收制剂 |
| EP3310348B1 (en) | 2015-06-22 | 2020-08-05 | Corium, Inc. | Transdermal adhesive composition comprising a poorly soluble therapeutic agent |
| JP6462880B2 (ja) | 2015-07-27 | 2019-01-30 | 久光製薬株式会社 | アセナピン含有貼付剤の製造方法 |
| US10966936B2 (en) | 2015-12-30 | 2021-04-06 | Corium, Inc. | Systems comprising a composite backing and methods for long term transdermal administration |
| CN105693556A (zh) | 2016-03-01 | 2016-06-22 | 巴斯特医药科技（常州）有限公司 | 卡巴拉汀酒石酸盐的转化方法及其产物制成的贴片 |
-
2017
- 2017-07-26 WO PCT/US2017/044047 patent/WO2018022814A1/en not_active Ceased
- 2017-07-26 AU AU2017302305A patent/AU2017302305A1/en not_active Abandoned
- 2017-07-26 US US15/660,928 patent/US20180028461A1/en not_active Abandoned
- 2017-07-26 CN CN201780059413.9A patent/CN109789134A/zh active Pending
- 2017-07-26 KR KR1020197004938A patent/KR102424270B1/ko active Active
- 2017-07-26 EP EP17751886.7A patent/EP3490559A1/en active Pending
- 2017-07-26 US US15/660,933 patent/US10016372B2/en active Active
- 2017-07-26 CA CA3031944A patent/CA3031944A1/en active Pending
- 2017-07-26 JP JP2019503999A patent/JP7469879B2/ja active Active
-
2022
- 2022-02-22 JP JP2022025574A patent/JP2022060428A/ja active Pending
- 2022-11-28 US US18/070,319 patent/US20230086303A1/en not_active Abandoned
-
2023
- 2023-06-09 AU AU2023203613A patent/AU2023203613A1/en not_active Abandoned
-
2024
- 2024-01-05 JP JP2024000683A patent/JP2024019737A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522024A5 (enExample) | ||
| US20220395469A1 (en) | Transdermal drug delivery system for ketamine | |
| RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
| JP6845162B2 (ja) | ケタミン経皮送達システム | |
| TWI244396B (en) | A composition for topical application of methylphenidate and a pharmaceutical composition for treating attention deficit disorder and attention deficit/hyperactivity disorder | |
| TWI241911B (en) | Sustained release ranolazine formulations | |
| AU2008267058C1 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| TWI302460B (en) | Pharmaceutical compositions and use thereof | |
| EP2550961A1 (en) | Solid preparation | |
| JP2020536953A5 (enExample) | ||
| US20120034276A1 (en) | Solid preparation | |
| WO2000064434A1 (en) | Percutaneous preparations containing oxybutynin | |
| JP2018500365A5 (enExample) | ||
| EP2412367A1 (en) | Solid preparation | |
| US20210251906A1 (en) | Pregabalin extended-release formulations | |
| JP2015526456A (ja) | アミノアルキルナイトラートの延長放出（Ｅｘｔｅｎｄｅｄｒｅｌｅａｓｅ）組成物 | |
| CA2438339A1 (en) | Use of buprenorphine for treatment of urinary incontinence | |
| TW201201806A (en) | Sustained release preparation | |
| WO2005032441A1 (en) | Transdermal delivery of oxybutynin in gel formulations | |
| CN113194950B (zh) | 早泄(pe)的治疗和预防 | |
| KR101151342B1 (ko) | 에페리손 함유 필름코팅정제, 및 이의 제조방법 | |
| AU2012201640B2 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| KR20160141044A (ko) | 실데나필 제어방출성 경구제제 | |
| KR20120103521A (ko) | 에페리손 함유 필름코팅정제, 및 이의 제조방법 |